Semaglutide Dosage: Studied Protocols and Titration Data

Dosing Frameworks Across the Trial Program

Semaglutide clinical trials used three distinct dosing frameworks depending on indication and formulation. The STEP program (obesity/weight management), the SUSTAIN program (type 2 diabetes, subcutaneous), and the PIONEER program (type 2 diabetes, oral) each used different starting doses, titration intervals, and maintenance targets.^[1][15]

FDA-approved indications and their labeled dose ranges are documented in this section. The FDA label for subcutaneous semaglutide for chronic weight management describes the titration below.

Semaglutide Dosing Protocols in Clinical Trials

FIG. 1 Abstract pharmacokinetic curve — the stepped titration rise to maintenance dose and subsequent broad plasma-concentration plateau characteristic of semaglutide's ~168-hour half-life.

STEP program — obesity weight management titration

As documented in the STEP trial protocol and FDA label for chronic weight management:^[1][15]

The slow 16-week escalation was designed to minimize gastrointestinal adverse events during initiation. STEP trial data show GI side effects were highest during dose escalation (weeks 1–20) and declined as participants reached and maintained the 2.4 mg maintenance dose.^[12]

SUSTAIN program — type 2 diabetes (subcutaneous)

As documented in SUSTAIN-6 and SUSTAIN FORTE trial protocols:^[6][22]

• Weeks 1–4: 0.25 mg subcutaneous once weekly (initiation dose; not therapeutically effective for glycemic control but tolerability-establishing)
• Weeks 5+: 0.5 mg maintenance; escalate to 1.0 mg if additional glycemic control needed
• SUSTAIN FORTE extended to 2.0 mg as a higher-dose option; 2.0 mg produced greater HbA1c reduction (−2.2%) versus 1.0 mg (−1.9%) and more weight loss (−6.9 kg versus −6.0 kg) in 961 patients over 40 weeks^[22]

PIONEER program — type 2 diabetes (oral)

As documented in PIONEER 1 and PIONEER 6 trial protocols:^[23][7]

• Initiation: 3 mg oral daily for 4 weeks
• Dose 2: 7 mg oral daily for 4 weeks or longer
• Maintenance: 14 mg oral daily (the only dose with full efficacy data; PIONEER 1 showed HbA1c reductions of −1.4 to −1.5% with 7 mg and 14 mg versus −0.1% placebo)
• Administration: taken 30 minutes before the first meal of the day, with water only; food, other liquids, or other oral medications taken within 30 minutes reduce absorption via SNAC competition^[8]

Semaglutide Half-Life and Duration of Action

Plasma half-life: approximately 145–168 hours across studied populations, with a mean of approximately 165 hours.^[8] The extended half-life is achieved via the C18 fatty-diacid side chain, which confers greater than 99% albumin binding at therapeutic concentrations and protects the molecule from DPP-4 enzymatic degradation and renal filtration.

Subcutaneous Tmax (time to peak plasma concentration): 24–72 hours after injection.^[8] Bioavailability of the subcutaneous formulation: approximately 89%.

Time to full clearance after the final dose: approximately 5 weeks (5 × half-life ≈ 825 hours, or 34 days).^[8] This extended clearance window is clinically relevant: effects on appetite, gastric emptying, and glucose regulation persist for 4–5 weeks after the last injection.

Renal or hepatic impairment does not require dose adjustment based on pharmacokinetic data — semaglutide is primarily eliminated via proteolytic degradation rather than renal or hepatic clearance pathways, and neither impairment significantly alters exposure in the studies reviewed.^[8]

How Long Does Semaglutide Stay in Your System?

Plasma half-life is approximately 165–168 hours (approximately 7 days), enabling once-weekly dosing with stable trough concentrations at steady state.^[8] Steady state is reached after 4–5 weekly doses — consistent with the 16-week titration schedule in STEP trials, which reaches maintenance dose approximately when steady-state pharmacokinetics are established.

After the final dose, detectable drug levels persist for approximately 5 weeks. The pharmacokinetic review by Yang and Yang (2024) across 16+ studies confirms clearance rate 0.030–0.047 L/h, volume of distribution approximately 12.5 L.^[8]

Reconstitution Protocols in Published Research

Research literature on lyophilized (compounded) semaglutide preparations documents reconstitution with bacteriostatic water. Standard research concentrations described: 5 mg/mL (1 mL added to a 5 mg vial) or 5 mg/mL (2 mL added to a 10 mg vial).^[13] The specific volume added determines the working concentration, and researchers document the volume on the vial or in the protocol.

Commercial pre-filled pens used in clinical trials are documented as stable at room temperature up to 30°C for up to 56 days after first use. Reconstituted research preparations were typically stored at 2–8°C and used within 28 days in research protocols.